BlueCrest Capital Management’s Amicus Therapeutics FOLD Stock Holding History

BlueCrest Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,422	Closed	-$68K	–	827
2016 Q2	$68K	Buy	+12,422	New	+$86.9K	﹤0.01%	830
2016 Q1	–	Sell	-16,912	Closed	-$164K	–	892
2015 Q4	$164K	Buy	+16,912	New	+$152K	0.01%	880
2015 Q2	–	Sell	-163,920	Closed	-$1.78M	–	828
2015 Q1	$1.78M	Buy	+163,920	New	+$1.44M	0.1%	271

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlueCrest Capital Management's FOLD Position: Q3 2016 in Review

BlueCrest Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2016, closing a stake of 12,422 shares — an estimated $68K sold.

BlueCrest Capital Management first reported a position in FOLD in Q1 2015 and held it in 3 quarters. The position peaked at $1.78M in Q1 2015. 136 funds tracked by Wall St. Rank hold FOLD as of Q3 2016.

BlueCrest Capital Management reported no remaining Amicus Therapeutics position as of Q3 2016 after selling out during the quarter.
BlueCrest Capital Management sold 12,422 Amicus Therapeutics shares in Q3 2016, an estimated $68K.
BlueCrest Capital Management first reported a position in Amicus Therapeutics in Q1 2015 and held it in 3 quarters.
BlueCrest Capital Management's Amicus Therapeutics position peaked at $1.78M in Q1 2015.
136 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2016.

Based on BlueCrest Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.